World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
23935
World Ranking
12376
National Ranking
6336

Ara A. Vaporciyan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ara A. Vaporciyan sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 627 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ara A. Vaporciyan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ara A. Vaporciyan sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ara A. Vaporciyan is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans various areas within medicine, with a strong focus on pulmonary and respiratory medicine, oncology, surgery, radiology, nuclear medicine, imaging, and cancer research.

Their work predominantly revolves around lung cancer diagnosis and treatment, lung cancer treatments and mutations, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, radiomics and machine learning in medical imaging, gastric cancer management and outcomes, as well as esophageal cancer research and treatment.

Frequent coauthors in their publications include Mara B. Antonoff, Boris Sepesi, Stephen G. Swisher, John V. Heymach, and Reza J. Mehran, indicating collaborations with experts in related fields.

They have published extensively in several journals and conferences, with frequent publication venues including:

  • Journal of Thoracic and Cardiovascular Surgery
  • The Annals of Thoracic Surgery
  • Journal of Thoracic Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology

Notable recent papers include:

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery, 2021, The Lancet Oncology
  • Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer, 2020, Journal of Clinical Oncology
  • Comprehensive T cell repertoire characterization of non-small cell lung cancer, 2020, Nature Communications
  • Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial, 2023, The Lancet

Best Publications

  • Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo

    Ara A. Vaporciyan;Horace M. DeLisser;Horng Chin Yan;Ignacio I. Mendiguren

  • C5a-induced expression of P-selectin in endothelial cells.

    Kimberly E. Foreman;Ara A. Vaporciyan;Brian K. Bonish;Michael L. Jones

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

    Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  • Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients

    Ara A Vaporciyan;Arlene M Correa;David C Rice;Jack A Roth

  • Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer

    Stephen G. Swisher;Mary Maish;Jeremy J. Erasmus;Arlene M. Correa

  • Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.

    Apar Pataer;Neda Kalhor;Arlene M. Correa;Maria Gabriela Raso

  • 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

    Stephen G. Swisher;Jeremy Erasmus;Mary Maish;Arlene M. Correa

  • Treatment Outcomes of Resected Esophageal Cancer

    Wayne Hofstetter;Stephen G. Swisher;Arlene M. Correa;Kenneth Hess

  • Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy

    Stephen G. Swisher;Paula Wynn;Joe B. Putnam;Melinda B. Mosheim

  • Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical Trial

    Charles S. Cleeland;Xin Shelley Wang;Qiuling Shi;Tito R. Mendoza

  • Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

    Stephen G Swisher;Jack A Roth;Ritsuko Komaki;Jian Gu

  • Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer

    Zhongxing Liao;J. Jack Lee;Ritsuko Komaki;Daniel R. Gomez

  • Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter

    Joe B. Putnam;Garrett L. Walsh;Stephen G. Swisher;Jack A. Roth

  • Tumor necrosis factor α regulates in vivo intrapulmonary expression of ICAM-1

    Michael S. Mulligan;Ara A. Vaporciyan;Masayuki Miyasaka;Takuya Tamatani

  • Management of primary pulmonary artery sarcomas.

    Shanda H. Blackmon;David C Rice;Arlene M Correa;Reza John Mehran

  • Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

    Shu Lian Wang;Zhongxing Liao;Ara A Vaporciyan;Susan L. Tucker

  • Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.

    David C. Rice;Craig W. Stevens;Arlene M. Correa;Ara A. Vaporciyan

  • Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.

    Joe Y Chang;Reza J Mehran;Lei Feng;Vivek Verma

  • Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters.

    Hoon K Lee;Ara A Vaporciyan;James D Cox;Susan L Tucker

  • Factors affecting interest in cardiothoracic surgery: Survey of North American general surgery residents.

    Ara A. Vaporciyan;Carolyn E. Reed;Clese Erikson;Michael J. Dill

Frequent Co-Authors

Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center
David C. Rice
David C. Rice The University of Texas MD Anderson Cancer Center
Jack A. Roth
Jack A. Roth The University of Texas MD Anderson Cancer Center
Garrett L. Walsh
Garrett L. Walsh The University of Texas MD Anderson Cancer Center
Wayne L. Hofstetter
Wayne L. Hofstetter The University of Texas MD Anderson Cancer Center
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Jaffer A. Ajani
Jaffer A. Ajani The University of Texas MD Anderson Cancer Center
Ritsuko Komaki
Ritsuko Komaki The University of Texas MD Anderson Cancer Center
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Joe B. Putnam
Joe B. Putnam The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing medicine in the USA can open doors to a wide range of health-related careers. Increasingly, students are exploring flexible and online degree options to expand their qualifications or specialize in key areas. For example, you can gain expertise in personal and public health by completing one of the best online nutrition programs, which prepare graduates for rewarding roles in dietetics and wellness.

Those interested in healthcare management may consider the top online mha programs that are cahme accredited, ensuring a recognized and high-quality education for future leaders. Registered nurses looking to advance can explore rn to bsn no clinical hours programs that offer academic advancement without the additional clinical requirements.

Finally, seasoned nurses with a master’s degree can reach the pinnacle of clinical practice more quickly with the shortest post master's dnp program options. Exploring these related degrees expands your career pathways in healthcare, no matter your stage or specialty.

Best Scientists Citing Ara A. Vaporciyan

Trending Scientists

Recently Published Articles